US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CAR-T Concept

1,432.11

+12.810.90%

Number of Gainers:3

Number of Losers:- -

Number of Flat:- -

PE:- -

High:1,438.74

Open:1,417.73

Low:1,415.68

Close:1,419.51

Loading ...

The Zacks Analyst Blog Highlights Charles Schwab, Gilead, Medtronic, Cooper-Standard and Rave Restaurant

Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors

Market Chatter: Emasan Offering to Sell 1.2% Stake in Novartis

MT Newswires Live

Novartis holder Emasan selling 26.5M shares, Bloomberg reports

Emasan files to sell 26.5M shares of Novartis, Bloomberg reports

4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty

Here's Why Novartis (NVS) is a Strong Momentum Stock

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects

Gilead Sciences Says Potential HIV Prophylaxis Applications Under Parallel Accelerated Review in EU

MT Newswires Live

European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for Hiv Prevention

THOMSON REUTERS

Gilead: Both Applications of Lenacapavir for Hiv Prevention Will Be Assessed in Parallel Under Accelerated Assessment Review Timeline

THOMSON REUTERS

European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention

bluebird bio Inc : JP Morgan Raises to Neutral From Underweight

THOMSON REUTERS

Gilead Sciences, Inc. (GILD): Among Renaissance Technologies Portfolio’s Top Stock Picks

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK4578/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4578"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1432.3206,"timestamp":1741628365094,"preClose":1419.5145,"halted":0,"volume":5635282,"delay":0,"changeRate":0.009021,"change":12.80603,"pbRate":5.836914,"amount":639372690.859266,"amplitude":0.016244,"prevYearClose":1164.883,"fiveDayClose":1375.8962,"twentyDayClose":1248.9824,"turnoverRate":0.001797,"marketCap":377842425136,"floatMarketCap":366829271428,"peRate":30.498118},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1438.7367,"amplitude":0.016244,"preClose":1419.5145,"low":1415.6777,"pbRate":"5.836914","latestPrice":1432.1082,"volume":5633637,"delay":0,"open":1417.7288,"prevYearClose":1164.883,"prevWeekClose":1419.5145,"prevMonthClose":1356.2184,"prevQuarterClose":1164.883,"fiveDayClose":1375.8962,"twentyDayClose":1248.9824,"sixtyDayClose":1184.3591,"secType":"PLATE","market":"US","turnoverRate":0.001797,"peRate":30.498118,"marketCap":377798827312,"floatMarketCap":366785771908,"timestamp":1741628360933,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":3,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514872836","title":"The Zacks Analyst Blog Highlights Charles Schwab, Gilead, Medtronic, Cooper-Standard and Rave Restaurant","url":"https://stock-news.laohu8.com/highlight/detail?id=2514872836","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514872836?lang=en_us&edition=fundamental","pubTime":"2025-02-26 18:39","pubTimestamp":1740566340,"startTime":"0","endTime":"0","summary":"Chicago, IL – February 26, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Charles Schwab Corp. SCHW, Gilead Sciences, Inc. GILD, Medtronic plc MDT, Cooper-Standard Holdings Inc. CPS and Rave Restaurant Group, Inc. RAVE.Top Stock Reports for Chas Schwab, Gilead and Medtronic. The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Pre-Markets Try Again to Ramp Higher","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-analyst-blog-highlights-charles-103900577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2271345857.HKD","LU0011850046.USD","LU2264538146.SGD","LU0320765489.SGD","LU0976567544.SGD","BK4139","LU0345774631.USD","SG9999014039.USD","BK4127","LU0265550359.USD","RAVE","LU0106831901.USD","LU0130102774.USD","IE00BSNM7G36.USD","BK4578","BK4568","LU1066053197.SGD","LU2089984988.USD","LU0648001328.SGD","LU0496365809.HKD","IE0002270589.USD","LU2468319806.SGD","LU1064131342.USD","IE00B7SZLL34.SGD","BK4124","LU1116320737.USD","NIM","IE00BQXX3F31.USD","IE00BZ1G4Q59.USD","LU0211331839.USD","SCHW","LU1116320901.HKD","CPS","LU1668664300.SGD","LU2089284900.SGD","LU0208291251.USD","LU1430594728.SGD","MDT","LU1989764748.USD","LU1069347547.HKD","BK4589","LU0072461881.USD","LU0266013472.USD","BK4532","BK4581","IE00BQXX3C00.GBP","LU1983299246.USD","GILD","LU2360107671.USD","BK4533"],"gpt_icon":0},{"id":"2514384268","title":"Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors","url":"https://stock-news.laohu8.com/highlight/detail?id=2514384268","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514384268?lang=en_us&edition=fundamental","pubTime":"2025-02-26 17:05","pubTimestamp":1740560700,"startTime":"0","endTime":"0","summary":"Chicago, IL – February 26, 2025 – Stocks in this week’s article are Gilead Sciences GILD, Exelixis EXEL, Synchrony Financial SYF and Molson Coors TAP.4 PEG-Based GARP Stocks to Weather 2025 Market Uncertainty. The new year has been turbulent so far for the equity market, with geopolitical tensions and trade policies playing a significant role in shaping investor sentiment. Trump's tariff policies have not only reignited trade conflicts with China but also resulted in retaliatory measures from the European Union. This has increased concerns over global supply chains and corporate earnings.Several stocks, which have surged significantly in the recent past, show an overwhelming success of this hybrid investing strategy over pure-play value and growth investments. Here, we will discuss the success of four such stocks. These are Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors.Unfortunately, this ratio is often neglected due to investors' limitations in calculating the future","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-com-featured-highlights-gilead-090500682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BZ1G4Q59.USD","LU0306807586.USD","GILD","BK4139","BK4561","IE00BMG7P926.USD","IE00BMG7P587.USD","IE00BD4GTV84.USD","LU0109394709.USD","LU0321505868.SGD","IE00B19Z3581.USD","LU0058720904.USD","LU1585245621.USD","LU0234570918.USD","LU0306806265.USD","LU0106831901.USD","LU1861217088.USD","LU2360107671.USD","BK4568","PEG","IE00BSNM7G36.USD","IE0002270589.USD","BK4550","IE00B19Z3B42.SGD","BK4585","LU0321505439.SGD","LU0985481810.HKD","LU1571399168.USD","LU1861220207.SGD","BK4208","LU2087621335.USD","LU1066051498.USD","BK4158","BK4578","EXEL","LU1430594728.SGD","LU1668664300.SGD","LU0225771236.USD","LU1839511570.USD","IE00B7SZLL34.SGD","SYF","IE00BKVL7J92.USD","LU0289739699.SGD","BK4588","LU0889565916.HKD","IE00BD4GTW91.USD","LU1066053197.SGD","LU1791807156.HKD","LU2468319806.SGD","TAP"],"gpt_icon":0},{"id":"2514554012","title":"Market Chatter: Emasan Offering to Sell 1.2% Stake in Novartis","url":"https://stock-news.laohu8.com/highlight/detail?id=2514554012","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514554012?lang=en_us&edition=fundamental","pubTime":"2025-02-26 01:19","pubTimestamp":1740503956,"startTime":"0","endTime":"0","summary":"Novartis  stakeholder Emasan is offering to sell around 26.5 million shares, or a 1.2% stake, in the pharmaceutical company, Bloomberg reported Tuesday.The deal could raise around 2.7 billion Swiss francs , based on Tuesday's closing share price, according to the report.Emasan is selling the stake through an accelerated placement with investors, the report said.Novartis did not immediately reply to a request for comment from MT Newswires.NVS shares were 0.8% higher in recent trading.Price: 110.09, Change: +0.87, Percent Change: +0.80","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","IE00BJJMRZ35.SGD","BK4588","BK4578","IE0009355771.USD","BK4585","IE0002141913.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4532","IE00BFTCPJ56.SGD","LU0211331839.USD","NVS","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2514012612","title":"Novartis holder Emasan selling 26.5M shares, Bloomberg reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2514012612","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514012612?lang=en_us&edition=fundamental","pubTime":"2025-02-26 01:13","pubTimestamp":1740503625,"startTime":"0","endTime":"0","summary":"Emasan AG is offering around 26.5M shares in Swiss Novartis (NVS) through Goldman Sachs, potentially raising $3B, Pablo Mayo Cerqueiro of Bloomberg...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-holder-emasan-selling-26-5m-shares-bloomberg-reports?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-holder-emasan-selling-26-5m-shares-bloomberg-reports?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","BK4585","IE00B4R5TH58.HKD","LU1868836757.USD","BK4533","IE0002141913.USD","LU2750360641.GBP","LU2471134796.USD","IE00BJJMRZ35.SGD","BK4532","BK4550","BK4516","LU0106831901.USD","IE0004086264.USD","IE0009355771.USD","IE00BSNM7G36.USD","BK4007","BK4504","LU2750360997.AUD","LU1868837136.USD","IE00BFTCPJ56.SGD","IE00BFXG1179.USD","LU1868836591.USD","LU2471134952.CNY","IE00BJT1NW94.SGD","LU1668664300.SGD","IE0002270589.USD","LU1868837300.USD","LU0061475181.USD","LU0211331839.USD","LU2237443978.SGD","LU1868836914.USD","BK4552","BK4578","LU2237443549.SGD","NVS","IE00B19Z3B42.SGD","LU2237443622.USD","LU2471134523.USD","LU2237443382.USD","IE0034235188.USD","LU0096364046.USD","IE00B2B36J28.USD","LU2471134879.HKD","LU2237443895.HKD","BK4588","IE0004091025.USD","LU2237438978.USD","LU1791807156.HKD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2514014279","title":"Emasan files to sell 26.5M shares of Novartis, Bloomberg reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2514014279","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514014279?lang=en_us&edition=fundamental","pubTime":"2025-02-26 00:50","pubTimestamp":1740502215,"startTime":"0","endTime":"0","summary":"11:49 EST Emasan files to sell 26.5M shares of Novartis (NVS), Bloomberg reports Published first on TheFly – the ultimate source for real-time, mar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/emasan-files-to-sell-26-5m-shares-of-novartis-bloomberg-reports?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/emasan-files-to-sell-26-5m-shares-of-novartis-bloomberg-reports?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009355771.USD","BK4007","IE00B4R5TH58.HKD","NVS","LU0211331839.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","BK4588","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4532","IE00B2B36J28.USD","BK4585","BK4578"],"gpt_icon":0},{"id":"2514012738","title":"4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=2514012738","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514012738?lang=en_us&edition=fundamental","pubTime":"2025-02-26 00:07","pubTimestamp":1740499620,"startTime":"0","endTime":"0","summary":"The new year has been turbulent so far for the equity market, with geopolitical tensions and trade policies playing a significant role in shaping investor sentiment. Trump's tariff policies have not only reignited trade conflicts with China but also resulted in retaliatory measures from the European Union. This has increased concerns over global supply chains and corporate earnings. Further, the Federal Reserve’s decision to hold interest rates steady, despite earlier expectations of a cut, has added to market uncertainty. Fed’s cautious approach suggests that inflationary pressure might still be at play, limiting its flexibility in easing monetary policy.In such a situation, investments always need to be prudently hedged in order to limit losses related to external shocks. A question that often arises is whether one should resort to a value strategy that seeks discounted stocks or opt for growth investing in times of extreme market instability. The investing track of the Oracle of Oma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/4-peg-based-garp-picks-160700050.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IE00BMG7P587.USD","TAP","IE00BMG7P819.SGD","LU0321505439.SGD","LU1861220207.SGD","LU0306807586.USD","LU0225284248.USD","GARP","LU1839511570.USD","LU2089984988.USD","BK4532","LU2087621335.USD","LU0225771236.USD","LU1066053197.SGD","IE00BD4GTV84.USD","LU0106831901.USD","PEG","EXEL","LU0889565916.HKD","LU1668664300.SGD","BK4566","BK4588","LU1791807156.HKD","IE00BMG7P926.USD","GILD","IE00BKVL7J92.USD","BK4585","LU0985481810.HKD","LU1585245621.USD","SYF","LU0234570918.USD","LU1571399168.USD","LU1066051498.USD","BK4568","BK4208","LU0289739699.SGD","BK4578","BK4166","LU0306806265.USD","IE00BMG7P694.USD","IE0002270589.USD","IE00B7SZLL34.SGD","LU2468319806.SGD","LU1861217088.USD","IE00BD4GTW91.USD","IE00B3T34201.USD","BK4550","IE00B19Z3B42.SGD","LU1430594728.SGD"],"gpt_icon":0},{"id":"2514481014","title":"Here's Why Novartis (NVS) is a Strong Momentum Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2514481014","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514481014?lang=en_us&edition=fundamental","pubTime":"2025-02-25 22:50","pubTimestamp":1740495008,"startTime":"0","endTime":"0","summary":"For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.Is This 1 Momentum Stock a Screaming Buy Right Now?For momentum investors, upward or downward trends in a stock's price or earnings outlook take precedent, so they'll want to zero in on the Momentum Style Score. This Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.This article originally published on Zacks Investment Research .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-novartis-nvs-strong-145008831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","BK4578","IE00B4R5TH58.HKD","BK4007","BK4585","BK4588","IE0002141913.USD","NVS","IE00BJT1NW94.SGD","LU0211331839.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2514774916","title":"NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects","url":"https://stock-news.laohu8.com/highlight/detail?id=2514774916","media":"Benzinga","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514774916?lang=en_us&edition=fundamental","pubTime":"2025-02-25 01:39","pubTimestamp":1740418773,"startTime":"0","endTime":"0","summary":"A cost-saving effort by NHS England to transition multiple sclerosis  patients from Biogen Inc’s  Tysabri  to the biosimilar drug Tyruko has led to significant side effects.At Charing Cross Hospital in London, about 170 multiple sclerosis patients experienced complications, including relapses, mobility issues, fatigue, pain, and weight gain. Some cases were severe enough to require hospitalization.Also Read: Biogen Strengthens Pipeline With Stoke Therapeutic’s Dravet Syndrome Candidate Via Multi-Million Dollar Deal. According to The Guardian report, NHS England has been rolling out biosimilar drugs like Tyruko since April, aiming to cut costs by using alternatives to patented medications. Biosimilars are designed to be as effective and safe as the original drugs but are considerably cheaper—Tyruko costs an average of 72% less than Tysabri.The extent of the issue remains unclear. NHS England has stated that problems have only been observed at Charing Cross, but one patient claims that i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nhs-englands-transition-biogens-drug-173933715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BKVL7J92.USD","BK4504","LU1162221912.USD","LU2028103732.USD","LU1363072403.SGD","LU1989772923.USD","LU0795875086.SGD","LU0320765992.SGD","IE00B4R5TH58.HKD","NVS","LU1074936037.SGD","IE00B19Z9Z06.USD","LU1732799900.SGD","LU2357305700.SGD","LU0158827781.USD","LU2347655156.SGD","IE00B19Z9P08.USD","BK4534","IE00BJT1NW94.SGD","LU0795875169.SGD","LU1720051017.SGD","IE00B894F039.SGD","BK4127","IE0009355771.USD","LU0320765646.SGD","LU0314104364.USD","BK4139","LU0211331839.USD","LU1989772840.SGD","LU0889565916.HKD","LU2111349929.HKD","LU0098860793.USD","LU0109394709.USD","LU0234570918.USD","LU2023251221.USD","BIIB","BK4581","LU0267386448.USD","IE0002141913.USD","LU0006306889.USD","LU1732800096.USD","LU0225283273.USD","LU2271345857.HKD","BK4578","LU2089284900.SGD","IE00BFTCPJ56.SGD","BK4533","LU0106261372.USD","LU2133065610.SGD","LU1668664300.SGD"],"gpt_icon":0},{"id":"2513722106","title":"Gilead Sciences Says Potential HIV Prophylaxis Applications Under Parallel Accelerated Review in EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2513722106","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513722106?lang=en_us&edition=fundamental","pubTime":"2025-02-24 22:39","pubTimestamp":1740407986,"startTime":"0","endTime":"0","summary":"Gilead Sciences  said Monday its two applications for lenacapavir as a pre-exposure prophylaxis to prevent HIV have been validated for parallel accelerated review by the European Medicines Agency.The company said one application is for a marketing authorization and another is an EU-Medicines for all, or EU-M4all, application to facilitate expedited review processes for the injectable HIV-1 capsid inhibitor in other countries outside the EU.Both applications are supported by phase 3 data that showed twice-yearly lenacapavir achieved risk reduction in HIV infections of 96% to 100%, the company added.Gilead Sciences said the EMA validation followed the acceptance by the US Food and Drug Administration of its new drug applications for lenacapavir.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1066051498.USD","GILD","BK4585","LU2468319806.SGD","IE00BKVL7J92.USD","LU1839511570.USD","LU2087621335.USD","LU1066053197.SGD","BK4532","IE00BZ1G4Q59.USD","LU0058720904.USD","LU2089984988.USD","IE00B7SZLL34.SGD","BK4550","LU0234570918.USD","IE00BSNM7G36.USD","LU0109394709.USD","LU1571399168.USD","IE0002270589.USD","BK4568","BK4583","LU0889565916.HKD","IE00B3T34201.USD","BK4578","LU0320765992.SGD","IE00B19Z3B42.SGD","BK4139","LU1585245621.USD","BK4566","BK4588","LU1430594728.SGD","LU0289739699.SGD","BK4156","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2513299007","title":"European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for Hiv Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2513299007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513299007?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:30","pubTimestamp":1740403801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUABNG9BW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BKVL7J92.USD","BK4550","IE0002270589.USD","IE00B7SZLL34.SGD","LU0320765992.SGD","IE00BZ1G4Q59.USD","BK4588","LU0289739699.SGD","LU1066053197.SGD","BK4139","IE00B3T34201.USD","LU0889565916.HKD","BK4566","BK4532","IE00B19Z3581.USD","LU0109394709.USD","LU0234570918.USD","LU1066051498.USD","BK4585","LU2087621335.USD","LU1585245621.USD","IE00B19Z3B42.SGD","BK4568","LU0058720904.USD","LU1430594728.SGD","BK4578","BK4583","LU1571399168.USD","LU1839511570.USD","IE00BSNM7G36.USD","GILD","LU2089984988.USD","LU2468319806.SGD"],"gpt_icon":0},{"id":"2513151729","title":"Gilead:  Both Applications of Lenacapavir for Hiv Prevention Will Be Assessed in Parallel Under Accelerated Assessment Review Timeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2513151729","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513151729?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:30","pubTimestamp":1740403801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUABNG9BW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","BK4578","BK4585","IE0002270589.USD","LU2089984988.USD","BK4550","BK4566","BK4588","LU1430594728.SGD","LU1585245621.USD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","LU0889565916.HKD","IE00BSNM7G36.USD","GILD","LU0234570918.USD","IE00B3T34201.USD","IE00BZ1G4Q59.USD","LU1066053197.SGD","LU1066051498.USD","LU2468319806.SGD","LU0058720904.USD","LU0109394709.USD","BK4532","LU2087621335.USD","LU0320765992.SGD","IE00BKVL7J92.USD","BK4139","LU0289739699.SGD","BK4568","IE00B7SZLL34.SGD","LU1839511570.USD","LU1571399168.USD"],"gpt_icon":0},{"id":"2513210957","title":"European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2513210957","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513210957?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:30","pubTimestamp":1740403800,"startTime":"0","endTime":"0","summary":"– One Application Seeks European Commission Authorization; Other Application Would Facilitate Availability in Low- and Lower-Middle-Income Countries –。The EMA validation follows the announcement last week that the U.S. Food and Drug and Administration  accepted Gilead’s New Drug Applications  for lenacapavir for PrEP and will assess them under priority review.The EMA applications are supported by data from the Phase 3 PURPOSE 1 and PURPOSE 2 trials conducted by Gilead. In PURPOSE 1 , data showed twice-yearly lenacapavir demonstrated zero infections in the lenacapavir group and 100% risk reduction and superiority compared to background HIV incidence  for the investigational use of HIV prevention in cisgender women. In PURPOSE 2 , there were two HIV infections in the lenacapavir group, demonstrating 99.9% of participants in the lenacapavir group did not acquire HIV infection, a 96% risk reduction in HIV infections, and superiority compared to bHIV among a broad and geographically diverse","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/european-medicines-agency-validates-gilead-133000551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1571399168.USD","BK4585","LU2468319806.SGD","LU0320765992.SGD","LU1430594728.SGD","CHMP","BK4215","BK4583","IE00B19Z3B42.SGD","BK4156","LU0289739699.SGD","LU1066053197.SGD","LU0234570918.USD","BK4087","BK4566","IE00BZ1G4Q59.USD","GILD","BK4568","IE00B19Z3581.USD","BK4550","LU0058720904.USD","BK4588","IE00B7SZLL34.SGD","BK4532","IE00BSNM7G36.USD","LU1585245621.USD","LU2089984988.USD","MAA","BK4578","MDCO","IE0002270589.USD","LU1066051498.USD","LU2087621335.USD","LU0889565916.HKD","LU0109394709.USD","BK4139","LU1839511570.USD","IE00B3T34201.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2513792033","title":"bluebird bio Inc : JP Morgan Raises to Neutral From Underweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2513792033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513792033?lang=en_us&edition=fundamental","pubTime":"2025-02-24 13:23","pubTimestamp":1740374629,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PF0A2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4578","BK4556","BK4139","BLUE"],"gpt_icon":0},{"id":"2513549527","title":"Gilead Sciences, Inc. (GILD): Among Renaissance Technologies Portfolio’s Top Stock Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2513549527","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513549527?lang=en_us&edition=fundamental","pubTime":"2025-02-24 02:14","pubTimestamp":1740334499,"startTime":"0","endTime":"0","summary":"We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take a look at where Gilead Sciences, Inc.  stands against other Renaissance Technologies portfolio's top stock picks.The American quant hedge fundRenaissance Technologiesis known for using statistical and mathematical tools to drive its investment programs. It was founded in 1982 by Jim Simons, a mathematician who worked as a code breaker for the US National Security Agency during the Cold War. As of December 31, Renaissance Technologies had a portfolio valued at over $67.5 billion.READ ALSO:Cathie Wood’s Stock Portfolio: 2025 Stock PicksandJim Cramer’s February Portfolio: Top 10 Stocks.We scanned Renaissance Technologies’ 13F portfolio, as of December 31, 2024. From there, we picked the top 10 stocks according to their stake value and ranked them in ascending order.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-inc-gild-among-181459552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","BK4139","LU0234570918.USD",".IXIC","LU1066053197.SGD","LU2087621335.USD","BK4578","BK4532","PBC","BK4550","TSYW.SI","LU2468319806.SGD","TQQQ","IE00BSNM7G36.USD","GILD","LU0289739699.SGD","USJW.SI","IE00B7SZLL34.SGD","PSQ","BK4566","BK4588","IE00B3T34201.USD","LU1066051498.USD","IE00BKVL7J92.USD","NVIW.SI","USAW.SI","BK4568","NQmain","LU0109394709.USD","LU0320765992.SGD","SQQQ","LU0058720904.USD","LU2089984988.USD","QID","IE00BZ1G4Q59.USD","IE00B19Z3581.USD","LU1430594728.SGD","QLD","LU1571399168.USD","BK4585","IE0002270589.USD","LU1839511570.USD","BK4583","LU0889565916.HKD","LU1585245621.USD","IE00B19Z3B42.SGD"],"gpt_icon":1}],"pageSize":16,"totalPage":3,"pageCount":3,"totalSize":46}]}}